<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01321996</url>
  </required_header>
  <id_info>
    <org_study_id>CE119/2008/0/Sper</org_study_id>
    <nct_id>NCT01321996</nct_id>
  </id_info>
  <brief_title>68Ga-DOTA-NOC PET/CT in Patients With Idiopathic Pulmonary Fibrosis</brief_title>
  <official_title>Employment of 68Ga-DOTA-NOC in Patients With Idiopathic Pulmonary Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS Azienda Ospedaliero-Universitaria di Bologna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS Azienda Ospedaliero-Universitaria di Bologna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aim to evaluate the role of 68Ga-DOTA-NOC PET/CT in patients with&#xD;
      idiopathic pulmonary fibrosis, in particular in patients with a diagnosis of IPF/UIP&#xD;
      (idiopathic pulmonary fibrosis, diagnosed based in the American Thoracic Society and European&#xD;
      Respiratory Society criteria) and in forms of NSIP (non-specific interstitial pneumonia).&#xD;
      PET/CT imaging data will be compared with HRCT (high-resolution computed tomography) findings&#xD;
      to assess disease extension, early disease detection and to non-invasively detect&#xD;
      somatostatin receptors expression at lung level in these patients, with potential therapeutic&#xD;
      implications.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Idiopathic pulmonary fibrosis prognosis remains severe, in particular for IPF, the most&#xD;
      common entity. Moreover, current treatment options are largely ineffective and do not change&#xD;
      the natural course of the disease. Pre-clinical evidence supports somatostatin receptors&#xD;
      expression in the lung of patients with IPF. Recently new PET tracers (Somatostatin analogues&#xD;
      labelled with 68Gallium), specifically binding to somatostatin receptors, have been developed&#xD;
      and are used in neuroendocrine tumours clinical trials.&#xD;
&#xD;
      Aim of the present study is to evaluate the role of 68Ga-DOTA-NOC PET/CT in patients with&#xD;
      idiopathic pulmonary fibrosis, in particular in patients with IPF/UIP and in cases with NSIP,&#xD;
      that are characterized by a more indolent progression. PET/CT data will be compared with HRCT&#xD;
      findings for the early detection of fibrotic areas and to non-invasively assess somatostatin&#xD;
      receptors expression at lung level in these patients, with potential therapeutic&#xD;
      implications. Moreover, the SUVmax (maximum standardized uptake value) will be analyzed in&#xD;
      comparison with disease site and extension on HRCT.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    enrollment failure (only 29 patients were enrolled during the study period)&#xD;
  </why_stopped>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Describe pattern of 68Ga-DOTA-NOC uptake in comparison with HRCT findings</measure>
    <time_frame>timeframe between imaging procedures 30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>68Ga-DOTA-NOC SUVmax correlation with pulmonary function tests</measure>
    <time_frame>timeframe between PET/CT and pulmonary fucntion tests 30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>68Ga-DOTANOC PET/CT in patients with IPF and NSIP</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>one arm study: all patients were studied by 68Ga-DOTANOC PET/CT</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>68Ga-DOTA-NOC PET/CT</intervention_name>
    <description>procedure: PET/CT scan with 68Ga-DOTA-NOC</description>
    <arm_group_label>68Ga-DOTANOC PET/CT in patients with IPF and NSIP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with a diagnosis of IPF and NSIP, based on the American Thoracic&#xD;
             Society/European Respiratory Society Consensus Conference&#xD;
&#xD;
          -  age â‰¥ 18 years&#xD;
&#xD;
          -  males/females&#xD;
&#xD;
          -  signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  breast feeding&#xD;
&#xD;
          -  healthy volunteers&#xD;
&#xD;
          -  paediatric cases&#xD;
&#xD;
          -  patients in emergency situations&#xD;
&#xD;
          -  patients legally incompetent&#xD;
&#xD;
          -  patients who refuse to sign the informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefano Fanti, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nuclear Medicine, Azienda Ospedaliero Universitaria di Bologna, Policlinico S.Orsola Malpighi, Bologna, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nuclear Medicine, Azienda Ospedaliero Universitaria di Bologna, Policlinico S.Orsola Malpighi</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Ambrosini V, Zompatori M, De Luca F, Antonia D, Allegri V, Nanni C, Malvi D, Tonveronachi E, Fasano L, Fabbri M, Fanti S. 68Ga-DOTANOC PET/CT allows somatostatin receptor imaging in idiopathic pulmonary fibrosis: preliminary results. J Nucl Med. 2010 Dec;51(12):1950-5. doi: 10.2967/jnumed.110.079962. Epub 2010 Nov 15.</citation>
    <PMID>21078794</PMID>
  </results_reference>
  <verification_date>January 2015</verification_date>
  <study_first_submitted>March 23, 2011</study_first_submitted>
  <study_first_submitted_qc>March 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2011</study_first_posted>
  <last_update_submitted>January 26, 2015</last_update_submitted>
  <last_update_submitted_qc>January 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS Azienda Ospedaliero-Universitaria di Bologna</investigator_affiliation>
    <investigator_full_name>Stefano Fanti</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>PET/CT</keyword>
  <keyword>68Ga-DOTANOC</keyword>
  <keyword>IPF</keyword>
  <keyword>NSIP</keyword>
  <keyword>Idiopathic pulmonary fibrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

